
April 20, 2021
BONESUPPORT awarded Synthetic Implantable Products agreement with Premier
—– This press release has been modified to comply with the Premier IR guidelines —–
Lund, Sweden, 13.00 CET, 20 April 2021 – BONESUPPORT™, an emerging leader i...
Read more
Read more

April 20, 2021
Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021
REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, tod...
Read more
Read more

April 20, 2021
Nordic Nanovector ASA – Share capital increase registered
Oslo, Norway, 20 April 2021
Reference is made to the stock exchange announcement on 12 April 2021 regarding the final result of Nordic Nanovector ASA's (OSE: NANOV) (the "Compa...
Read more
Read more

April 20, 2021
Vicore Pharma to host Key Opinion Leader webinar on C21 for the treatment of COVID-19
2021-04-20
KOL webinar being held on Wednesday, April 28[th] @ 14:00 CET (8 am EST) Gothenburg, April 20, 2021 – Vicore Pharma Holding AB (publ) (“Vicore”), a pharmaceuti...
Read more
Read more

April 16, 2021
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
STOCKHOLM — April 16, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hema...
Read more
Read more

April 15, 2021
Vicore Pharma publishes the Annual Report for 2020
Gothenburg, April 15, 2021 – Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fib...
Read more
Read more

April 13, 2021
BONESUPPORT Holding AB publishes Annual Report 2020
Lund, Sweden, 16:00 CET, 13 April 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, announces that the An...
Read more
Read more

April 12, 2021
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
- Mirum expands potential opportunities across rare disease pipeline
- Vivet to lead preclinical development of its two gene therapy programs for PFIC3 and PFIC2
- Mirum...
Read more
Read more

April 12, 2021
Nordic Nanovector ASA – Final results of the repair offering
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AN...
Read more
Read more

April 10, 2021
Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy In Multiple Preclinical Tumor Models
Product candidate FPI-1434, when administered with olaparib, resulted in enhanced efficacy against colorectal and lung cancer xenografts
Combination of IGF-1R targeted alpha...
Read more
Read more